B+
Bull case
20%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
HLF
HerbalifeCNYSE / Household & Personal Products
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+68.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.8
Score
AI commentary
The earnings print was operationally constructive but not a clean upgrade: growth and constant-currency execution beat guidance, while reported EBITDA guidance narrowed because of FX. The observed post-print price reaction was positive, with HLF at $12.35 on August 7 versus the $11.51 August 6 anchor, but no trusted source in the packet attributed the move specifically to earnings. Post-print analyst revisions, target changes, and estimate changes were unavailable, so this remains a tentative monitoring view.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 2026 earnings beat with mixed guidance revisionMedium impact
Herbalife's August 5 SEC 8-K exhibit reported Q2 net sales of $1.3 billion, adjusted EBITDA of $166.6 million, and constant-currency results above guidance. Full-year adjusted EBITDA guidance narrowed for reported FX effects while constant-currency guidance increased. A bounded market-data check showed $12.35 on August 7, approximately 7.3% above the prior close. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1180262/000121390026085702/ea030059301ex99-1.htm
2026-12-31eventCash generation and deleveraging follow-throughMedium impact
The company reported year-to-date operating cash flow of $146.7 million after the April refinancing. Further evidence of cash conversion and leverage reduction could support valuation, while refinancing benefits depend on sustained operating performance. [#SEC-8K-2026-05-06] [#SEC-8K-2026-08-05]
2026-12-31catalystBioniq and personalized-nutrition rolloutHigh impact
The company reported Bioniq GO launches across EMEA and North America, Pro2col platform enhancements, and an at-home blood-test beta. Sustained adoption could support growth, but execution and distributor uptake remain unproven. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology